Please try another search
For the three months ended 31 March 2016, Anacor Pharmaceuticals Inc revenues increased 15% to $17.5M. Net loss increased 25% to $16.1M. Revenues reflect Distribution and commercialization agree increase of 22% to $14.7M. Higher net loss reflects Other General and administrative increase of 54% to $8.9M (expense), Stock-based Compensation in SGA increase of 39% to $3.3M (expense).
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 17.54 | 21.2 | 24.55 | 21.34 |
Gross Profit | 16.61 | 19.21 | 23.96 | 20.66 |
Operating Income | -14.92 | -17.62 | -14.95 | -12 |
Net Income | -16.15 | -18.91 | -16.18 | -13.2 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 176.1 | 188.48 | 195.78 | |
Total Liabilities | 123.81 | 132.71 | 130.5 | |
Total Equity | 52.29 | 55.77 | 65.28 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 0 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -56.27 | -42.29 | -18.07 | |
Cash From Investing Activities | 83.02 | 31 | 5.23 | |
Cash From Financing Activities | 10.94 | 5.51 | 4.34 | |
Net Change in Cash | 37.69 | -5.78 | -8.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review